Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

5661 - Targeted therapies in conversion therapy in mCRC: A systematic review and meta-analysis

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Presenters

Baocai Xing

Citation

Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281

Authors

B. Xing1, B. Cui2, Z. Gu3, H. Peng4

Author affiliations

  • 1 Department Of Gastrointestinal Surgery, Xiangya Hospital of Central South University, 410013 - Changsha/CN
  • 2 Oncology, 3rd Affiliated Hospital of Harbin Medical University, 150081 - Harbin/CN
  • 3 An Affiliate Of Merck Kgaa, Merck Serono Co. Ltd, Darmstadt/DE
  • 4 Hepatopancreatobiliary Surgery, Peking University Cancer Hospital, Beijing/CN
More

Resources

Abstract 5661

Background

Chemotherapy (CT) plays a vital role as conversion treatment for initially unresectable or borderline resectable colorectal cancer (CRC). Targeted therapies are recommended with CT for conversion therapy; however, their role in conversion of initially unresectable tumours has not been elucidated. This meta-analysis evaluated the role of targeted therapies for conversion aimed at R0 resection in KRAS WT mCRC.

Methods

We conducted a literature search for randomized controlled trials (RCTs) in PubMed, Embase and Cochrane library evaluating the role of anti EGFR and anti VEGF as conversion therapies. A comparison was performed for anti-EGFR + CT vs. anti-VEGF + CT (Gp. A) and anti-EGFR + CT vs. CT (Gp. B). R0 resection rate and objective response rate (ORR) were the primary outcomes; with overall survival (OS), progression free survival (PFS) and safety evaluated as the secondary outcomes. Primary outcomes and safety were presented as relative risk (RR) and 95% confidence interval (CI), whereas survival was presented as hazard ratio (HR) and 95%CI.

Results

We identified 8 RCTs from the potential 81 studies. In Gp. A, a fixed effects model was used for analysis; and showed that although non-significant, anti EGFR + CT had better R0 resection rate (RR 1.44, 95% CI 0.91,2.27; p = 0.1156; I2 = 0%) and ORR (RR 1.05, 95% CI 0.88, 1.24; p = 0.6039; I2 = 0%) compared with anti VEGF + CT. OS with anti EGFR + CT was significantly longer than anti VEGF + CT (HR: 0.64; CI 0.47, 0.86; p = 0.0036; I2 = 0%); however, PFS was numerically better in anti EGFR + CT. Compared with CT alone, anti EGFR + CT resulted in significantly higher R0 resection rate (RR 1.85, 95% CI 1.15,2.98; p = 0.0107; I2 = 57.16%) and ORR (RR 1.19, 95% CI 1.11, 1.28; p < 0.0001; I2 = 0%). In Gp. B, only PFS was significantly longer with anti EGFR + CT vs. CT (HR: 0.85; 95% CI 0.74, 0.98; p = 0.0015; I2 = 45.60%), and not OS. Safety evaluation showed anti EGFR + CT with significantly greater adverse events than CT alone (RR: 1.26; 95% CI: 1.18, 1.35; p < 0.0001).

Conclusions

In conclusion, anti EGFR + CT was an effective conversion therapy compared with anti VEGF + CT and CT in patients with initially unresectable mCRC; however, frequency of AEs was more with targeted therapy.

Clinical trial identification

Legal entity responsible for the study

Merck Serono Co. Ltd.

Funding

Merck Serono Co. Ltd.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.